The largest public-private partnership in the world has been formed, and its purpose is progress in the fight against antimicrobial resistance. As discussed in a Contagion article, ‘World’s Largest Partnership Formed to Fight Antimicrobial Resistance‘, the US Department of Health and Human Services issued a press release announcing CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a union of the Wellcome Trust of London, the AMR Centre of Alderley Park, and Boston University School of Law which will be headquartered in Boston.
The focus of this new global project is research and development of antimicrobial products to later be approved by the FDA. CARB-X is aiming to construct a portfolio of about twenty antibacterial products, at which point they will be moved quickly through the preclinical testing process and on to clinical development. Applications will be reviewed this September for these twenty antibacterial products.
Contributions to this effort will also be made by BARDA, and the National Institute of Allergy and Infectious Disease (NIAID). What makes this collaboration so monumental, aside from its size, is the diversity of participating organizations. This type of cooperation is exactly what is needed to propel progress forward in the AMR space. CARB-X is set to gather government, academia, and industry working toward a common goal. Other participating organizations are MassBio, CLSI, RTI International, and The Broad Institute of MIT.
The CARB-X executive team will be led by Kevin Outterson of Boston University School of Law, who is described in the article as a health law researcher and a global project collaborator. Mr. Outterson, as well as representatives from HHS, NIAID/NIH, FDA, BARDA, and the Review on AMR will also be speaking at the World Anti-Microbial Resistance Congress USA 2016 as part of a panel session entitled, ‘Will hybrid and delinkage economic models for anti-infectives get more pharma and VC’s back into the space?’ To hear more from Mr. Outterson and other leaders in the AMR space, and be a part of the conversation on fighting AMR, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington DC.